AZ's lesinurad meets in more Phase III gout trials

AstraZeneca plc (LSE:AZN; NYSE:AZN) said once-daily lesinurad ( RDEA594) met the primary endpoint in three Phase III trials to treat symptomatic gout. In the CLEAR1 and CLEAR2 trials, 200 and 400 mg lesinurad plus allopurinol improved the proportion of patients achieving serum uric acid (sUA) levels below 6 mg/mL at month six vs. allopurinol alone (p<0.0001). The trials each enrolled about 600 symptomatic gout patients not achieving target sUA levels on allopurinol.

The pharma also reported that in 324 gout patients with tophi in the CRYSTAL trial, high-dose lesinurad plus febuxostat improved the proportion of patients achieving target sUA levels below 5 mg/mL at month six vs. febuxostat alone (p<0.0001). Low-dose lesinurad missed the endpoint (p=0.13). Tophi are visible nodules of uric acid crystals that are deposited in joints and skin. ...